Cystic Fibrosis Foundation issued the following clinical trial alerts in March.
March 4, 2020
Status: Enrolling
Description: This study is taking place at multiple care centers across the U.S. It will look at the safety and tolerability of IV gallium, a drug intended to treat infections in the lung.
Age: 18 Years and Older
Mutation: No Mutation Requirement
Fev1% Predicted: 25% or greater
Number of Visits: 8
Length of Participation: 20 weeks
ClinicalTrial.gov link: https://clinicaltrials.gov/ct2/show/NCT04294043
March 6, 2020
Status: Completed with results
Description: This study evaluated the safety and tolerability of the drug PTI-428. This study was for people with CF ages 18 and older who have two copies of the F508del CFTR mutation and were already taking tezacaftor/ivacaftor (Symdeko®). A key goal of the study was to determine if PTI-428 could increase the amount of CFTR protein produced in people who were already taking tezacaftor/ivacaftor (Symdeko®).
Age: 18 Years and Older
Mutation: Two Copies F508del
Fev1% Predicted: 40 to 90%
Number of Visits: 10
Length of Participation: 74 days
ClincalTrials.gov link: https://clinicaltrials.gov/ct2/show/NCT03591094
Phase 1b study of inhaled AZD5634 in adults with CF
Status: Completed with results
Description: This study evaluated the safety and tolerability of the inhaled drug AZD5634 in people with CF. It also evaluated the effect of AZD5634 on improving the ability to clear mucus from the lungs (lung mucociliary clearance – MCC).
Age: 18 Years to 60 Years
Mutation: No Mutation Requirement
Fev1% Predicted: 40% or greater
Number of Visits: 4
Length of Participation: 4 months
ClincalTrials.gov link: https://clinicaltrials.gov/ct2/show/NCT02950805
March 23, 2020
Status: Completed with results
Description: This study evaluated the effectiveness and safety of the drug, PTI-808 in combination with PTI-801, with or without PTI-428. This study was for people with CF ages 18 and older who have at least one copy of the F508del CFTR mutation.
Age: 18 Years and Older
Mutation: Two Copies F508del or One Copy F508del
Fev1% Predicted: 40 to 90%
Number of Visits: 9
Length of Participation: 10 weeks
ClinicalTrial.gov link: https://clinicaltrials.gov/ct2/show/study/NCT03251092